Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tianda Pharmaceuticals Ltd. ( (HK:0455) ) has provided an announcement.
Tianda Pharmaceuticals Limited has called its annual general meeting for 12 June 2026 in Hong Kong, where shareholders will review the audited consolidated financial statements and reports for the year ended 31 December 2025. The agenda also includes re-election of executive, non-executive and independent non-executive directors, approval of directors’ remuneration for 2026, and re-appointment of Ernst & Young as auditor.
Shareholders will additionally vote on granting the board a general mandate to repurchase up to 10% of the company’s issued shares, excluding treasury shares, on the Hong Kong Stock Exchange or other recognised exchanges. The proposed buyback authority, which would run until the next AGM or its earlier revocation, is intended to provide the board with flexibility in managing capital structure and enhancing shareholder value, subject to applicable laws and listing rules.
More about Tianda Pharmaceuticals Ltd.
Tianda Pharmaceuticals Limited is a Hong Kong-listed pharmaceutical company incorporated in the Cayman Islands. The group operates in the healthcare and pharmaceuticals industry, focusing on the development, manufacture and sale of pharmaceutical products, with its shares traded on the Main Board of the Stock Exchange of Hong Kong.
Average Trading Volume: 96,100
Technical Sentiment Signal: Sell
Current Market Cap: HK$208.6M
Find detailed analytics on 0455 stock on TipRanks’ Stock Analysis page.